Polivy struck by NICE ‘no’
NICE is citing “substantial uncertainty in the submitted data” as a reason not to recommend the drug, as well as a lack of “strong long-term evidence on remission with the treatment.”
Read More
Tag: recommend
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
